Centene (CNC) 2024 Wells Fargo Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
2024 Wells Fargo Healthcare Conference summary
22 Jan, 2026Business performance and outlook
Q3 is tracking similarly to Q2, with full-year adjusted EPS expected to exceed $6.80, despite ongoing Medicaid pressure from redeterminations, offset by strong Marketplace, SG&A, and investment income performance.
Medicaid membership is expected to level off around 13.0 million, lower than previous projections, due to attrition and a 30% rejoiner rate, which is causing gaps in coverage and premium collection.
Marketplace business continues to perform strongly, with positive pricing strategy for 2025 and CMS adoption of the Agent of Record lock, enhancing stability for members.
Medicare and PDP bids for 2025 are on track, with strategic decisions to eliminate broker commissions for PDP due to IRA changes, while maintaining full commissions for Medicare Advantage.
Stars ratings are improving year-over-year, with meaningful progress expected toward the goal of 85% of members at 3.5+ Stars by October 2025.
Medicaid trends and rate dynamics
Medicaid HBR is under pressure from redeterminations, administrative terminations, and program changes in states, such as pharmacy benefit carve-outs and GLP-1 additions.
Rate updates are ongoing, with 4%+ increases expected in the back half of the year, but more is needed to reach long-term margin targets.
States are increasingly responsive to advocacy, with most having acted on rate adjustments, though sufficiency remains a challenge.
The path to normalized Medicaid margins may extend into 2026, requiring multiple rate cycles and continued data sharing with states.
Internal levers, such as operational discipline and advocacy, are being used to manage through the unprecedented redetermination environment.
Marketplace and exchange business
Marketplace performance is robust, with margin preservation prioritized for 2025 and a rigorous county-by-county approach to growth.
Enhanced subsidies have driven growth, and bipartisan support is expected to help maintain stability, even if federal policy changes.
Product design and state-based exchange strategies are being developed to mitigate potential subsidy loss impacts.
ICHRA market is growing, especially among small businesses and rural communities, aligning with a bottom-up growth strategy.
The company is prepared with multiple contingency plans to maintain target margins regardless of policy shifts.
Latest events from Centene
- 2026 EPS guidance reaffirmed; core businesses on track, with focus on fraud prevention and risk adjustment.CNC
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - 2026 guidance targets adjusted EPS above $3.00, strong revenue, and continued debt reduction.CNC
Q4 20256 Feb 2026 - 2025 EPS guidance exceeds $7.25, with revenue at $154–$156B and Duals, ICHRA driving growth.CNC
Investor Day 20243 Feb 2026 - Q2 EPS up 15% to $2.42; revenue $39.8B; Marketplace growth offsets Medicaid declines.CNC
Q2 20242 Feb 2026 - International growth, pipeline innovation, and diversification drive long-term value.CNC
Bank of America Global Healthcare Conference 202420 Jan 2026 - Q3 adjusted EPS hit $1.62, with strong Marketplace and Medicare PDP growth and robust share repurchases.CNC
Q3 202418 Jan 2026 - 2024 EPS rose 7% to $7.17; 2025 revenue outlook up $4B on strong Marketplace and Medicare.CNC
Q4 20249 Jan 2026 - 2025 EPS guidance reaffirmed above $7.25, with strong market positioning and policy engagement.CNC
Barclays 27th Annual Global Healthcare Conference 202520 Dec 2025 - Q1 2025 adjusted EPS up 28% to $2.90, revenue up 17% to $46.6B, guidance raised.CNC
Q1 202520 Dec 2025